Compare Fabrinet (FN) vs Oscar Health Inc (OSCR) Price & Performance

Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.

FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.

Oscar Health (OSCR) trades at $30.73, down 1.09% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong revenue growth, with 2026 revenue projected at $13.3 billion, but remains unprofitable with a net margin of -0.3%. Recent news highlights its momentum, including a 102.8% year-to-date gain and positive coverage from The Motley Fool and Zacks.

The outlook is mixed: strong revenue growth and bullish technicals offer upside potential, but profitability challenges and a consensus price target below the current price signal caution. Key risks include execution in a competitive insurance market and sustained losses. Analyst sentiment is divided, with a hold-heavy consensus.